Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of enzalutamide, versus a
conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone
releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation
therapy (ADT) for newly diagnosed metastatic prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sydney
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group Cancer Trials Ireland National Health and Medical Research Council, Australia NCIC Clinical Trials Group